
Neurogenesis, Inc. 
 Acción · US64124F3010    (OTC)
                    Sin cotización
                
                        Precio de cierre OTC 03.11.2025:
                        0,0001 USD
                    
 
            03.11.2025 21:00
        
Cotizaciones actuales de Neurogenesis, Inc.
| Bolsa | Ticker | Moneda | Última operación | Precio | Variación diaria | 
|---|---|---|---|---|---|
UTC  | 
                                NEUN
                              | 
                                USD
                              | 
                                03.11.2025 21:00
                              | 
                                0,0001 USD
                              | 0,00 USD   | 
        Perfil de la empresa para Neurogenesis, Inc. Acción
    
 Neurogenesis, Inc. manufactures and sells nutritional supplements primarily in the United States. The company offers NeuBecalm'd, a nutritional supplement to reduce the effects of acute and chronic stress factors; NeuBecalm'd Chewables that reduces the effects of stress and enhance focus; and NeuRecover, a nutritional support for the natural replenishment of neurotransmitters depleted by the long-term use of alcohol. It also provides NeuReplenish, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of chemical stimulants; NeuRelieve, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the long-term use of antianxiety drugs, and to be used in conjunction with professional support during the tapering process; and NeuSlim, which aids in the reduction of cravings (or urges) for simple carbohydrates, to reduce excessive appetite in general, and to assist in healthy moderation of nutritional needs. In addition, the company offers NeuBecalm'd/NeuRelieve Combo, a nutritional support for restoring and rebuilding healthy brain chemistry that has been altered or depleted by the prolonged use of prescription pain pills or from the use of opiate drugs, such as heroin or methadone, as well as used in conjunction with professional support during the tapering process. Neurogenesis, Inc. has a research collaboration with the University of Edinburgh for the development of various platform approaches to enable gene therapies. The company was founded in 1984 and is headquartered in League City, Texas.
 Datos de la empresa
Nombre Neurogenesis, Inc.
 Empresa Neurogenesis, Inc.
  Sitio web 
                            https://www.neurogenesis.com
                        
 Mercado principal 
                        UTC
                    
  ISIN US64124F3010
 Tipo de valor Acción
     Sector Healthcare
 Industria Drug Manufacturers - Specialty & Generic
 CEO Tal Gilat
  País Estados Unidos de América
 Moneda USD
 Empleados -
 Dirección 1241 Butler Road, 77573 League City
 Fecha de OPV 1998-06-08
Símbolos de cotización
| Nombre | Símbolo | 
|---|---|
| Over The Counter | NEUN | 
            Otras acciones
            
 
                Los inversores que tienen Neurogenesis, Inc. también tienen las siguientes acciones en su cartera:
            
            La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras.
 Desde depósitos de valores hasta compras de criptomonedas.
            
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
 Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.


